Progenics Pharma (PGNX) : FDA extends review of the New Drug Application for AZEDRA
Progenics Pharma announces that they have received notification from the FDA that the Agency will extend its review of the New Drug Application for AZEDRA (iobenguane I 131) by three months to July 30, 2018
No comments:
Post a Comment